The role of anti-peripheral nerve myelin antibody (anti-PNM Ab) in the pathogenesis of acquired demyelination of peripheral nerve is unclear, in part, due to the poor correlation between antibody and disease activity. Previous studies show that only 27-50% of patients with acute demyelinating neuropathy or Guillain-Barre syndrome (GBS) had serum Abs to peripheral nerve or PNM as demonstrated by consumption of hemolytic activity of serum complement. In the present study by the use of a complement component 1 (Cl) fixation and transfer assay, quantitative determinations of anti-PNM Ab showed significantly high titers in the serum of patients with GBS, chronic and recurrent polyneuritis, and paraproteinemia associated with peripheral neuropathy. All 11 patients with acute-phase GBS had Ab titers 6-56 times higher than controls. In 6 GBS patients, serial Ab determinations showed that titers were highest on admission, fell rapidly the first week, and became undetectable or barely detectable by the third week. Declining Ab titers coincided with cessation of clinical progression. In 3 GBS patients, depletion of serum IgM lowered anti-PNM Ab titers significantly, whereas IgG depletion failed to produce a similar effect. This study shows that the C1 fixation and transfer assay is a sensitive method to detect anti-PNM Ab in the serum of patients with a variety of demyelinating neuropathies and provides good correlation between Ab level and the clinical course of GBS patients. It may provide important information about the pathogenesis of the demyelinating neuropathies.
11 patients with acute-phase GBS had Ab titers 6-56 times higher than controls. In 6 GBS patients, serial Ab determinations showed that titers were highest on admission, fell rapidly the first week, and became undetectable or barely detectable by the third week. Declining Ab titers coincided with cessation of clinical progression. In 3 GBS patients, depletion of serum IgM lowered anti-PNM Ab titers significantly, whereas IgG depletion failed to produce a similar effect. This study shows that the C1 fixation and transfer assay is a sensitive method to detect anti-PNM Ab in the serum of patients with a variety of demyelinating neuropathies and provides good correlation between Ab level and the clinical course of GBS patients. It may provide important information about the pathogenesis of the demyelinating neuropathies.
The primary demyelination of peripheral nerve seen in patients with Guillain-Barre Syndrome (GBS) or chronic and recurrent polyneuropathy is thought to represent immunologically mediated myelin destruction (1, 2) . The role of the cellular and humoral immune system in initiation of myelin breakdown has not been defined. Antibodies (Abs) against peripheral nerve (3, 4) , peripheral nerve myelin (PNM) (4) (5) (6) , dorsal root ganglia (7) , spinal cord tissue components (3) , and neuroblastoma cells (8) have been identified in the serum of some GBS patients. However, it is not known whether these Abs actively participate in myelin destruction or whether they are an epiphenomenon reflecting a host response to PNM antigen(s) following myelin destruction. Recently a putative function for anti-PNM Abs in demyelination has been advanced by findings that some patients with monoclonal gammapathy develop demyelination and the monoclonal immunoglobulins are directed against PNM (6, 9) . Serum from GBS patients as well as serum from patients with paraproteinemia associated with peripheral neuropathy can induce segmental demyelination following intraneural injection into rat and cat sciatic nerves (10) (11) (12) (13) .
A reasonable hypothesis states that complement-activating, anti-PNM Abs may participate in peripheral nerve demyelination, particularly in light of the growing information on the membrane attack function of activated C5b-9 (14) and the C5b-9 requirement for Ab-mediated demyelination of mouse cerebellum explant cultures (15) . To test this hypothesis, it was necessary to determine the frequency of anti-PNM Abs present in patients with demyelinating peripheral neuropathy, the kinetic dynamics of such Ab titer during the course of illness, and finally the possible relationship between Ab titer and disease severity.
In two previous studies (3, 6) , serum Abs to peripheral nerve and PNM were measured by a conventional complement fixation method that involves a differential measurement between complement activity in the control and the test proper. In this method, a test result can be taken as positive only when the difference is substantial, which creates a blind zone with respect to detection of minute amounts of antigen-Ab complex. By contrast, the complement component 1 (Cl) fixation and transfer (C1FT) assay measures fixation of C1 directly (16) , which eliminates the blind zone. Thus, the C1FT assay is superior for detecting small quantities of Ab in patients' sera, and this is the reason the ClFT test was used in the present studies for assaying specific Abs to PMN. We studied the prevalence of such Ab in the serum of patients with various types of demyelinating neuropathies. It was possible to quantitate the anti-PNM activity and follow the dynamic kinetics of this Ab in GBS patients during the course of illness.
MATERIALS AND METHODS
Collection of Clinical Material. Serum was collected from 11 patients meeting the criteria of the Ad Hoc Committee for GBS (17) during the acute phase of their illness. Neurologic symptoms of these GBS patients developed over a 2-to 4-week period, plateaued, and then slowly resolved over several months, as generally observed in GBS patients. Clinical presentations were varied and included a classic ascending paralysis with respiratory involvement, symmetrical multiple cranial neuropathy, moderate proximal weakness, and the Miller-Fisher syndrome of opthalmoplegia associated with ataxia. None was treated with either plasmapheresis or immunosuppression. Serum was stored at -70°C. Prior to use (as a source of antibody) the serum was heat-inactivated at 56°C for 60 min. Serum was also obtained from 5 patients with monoclonal gammapathy with demyelinating peripheral neuropathy, 3 with IgM and 2 with IgG paraproteinemia, and Abbreviations: Ab, antibody; C1, C2, etc., complement components; C2D-HS, human serum congenitally deficient in C2; GBS, Guillain-Barre syndrome; PNM, peripheral nerve myelin.
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Determination of Cl-Fixing Anti-PNM Abs in Patients' Serum. In a standard assay, a fixed amount of PNM was incubated overnight with varying dilutions of heated human serum (at 56°C for 60 min) in a total volume of 500 ,ul at 4°C. The myelin was washed three times with G/barbital/NaCl by centrifugation in a Beckman Microfuge, model B, for 4 min, and the pellet was resuspended in 300 ,l of C2D-HS, as a source of excess C1, diluted 1:500 with G/barbital/NaCl, and then incubated for 30 min at 37°C. Unlike the original procedure (16) (Fig. 3) . In 1 patient, serum obtained during the plateau phase of GBS in the fourth week of disease showed no significant Ab. Ab titers were also elevated in 3 of 4 patients with the chronic and recurrent forms of polyneuritis and in 5 of 5 patients with paraproteinemia associated with demyelinating neuropathies.
Control serum was obtained from 9 laboratory personnel without known disease. In this group, 7 had titers of zero (no lysis of EAC4b,3b cells with undiluted serum). Two others had low but measurable titers of Ab, 4 and 5, respectively. Ab was also measured in serum of patients with a variety of other diseases, including 2 patients with systemic lupus erythematosis, 3 with rheumatoid arthritis, 1 with sarcoid, 1 with alcoholic neuropathy, 2 with paraproteinemia without neuropathy, 1 carpal tunnel syndrome, 1 with poliomyelitis with quadriparesis, and 1 with wound botulism. Among these controls, 4 with measurable titers were those patients with carpal tunnel syndrome, wound botulism, and 2 of the 3 rheumatoid arthritis; titers were 8, 10, 2, and 4, respectively. Seven of 12 patients, 1 with systemic lupus erythematosis, 1 with sarcoidosis, 1 rheumatoid arthritis, 1 with alcoholic neuropathy, 2 with cancer, and 1 with carpal tunnel syndrome had clinically significant neuropathies. Among these, only the carpal tunnel patient had any measurable anti-PNM Abs.
Kinetics of Serum Anti-PNM Ab in 6 GBS Patients. Abs were measured three or more times during the course of disease in 6 patients. Titers were all highest on admission, fell precipitously over the first 2 weeks, and then became either unobtainable or very low by the third and fourth weeks (Fig.  4) . Low The study demonstrated anti-PNM Ab in the serum of patients with a variety of demyelinating neuropathies (Fig. 3) and showed that Ab levels in these patients are greatly increased compared with control groups, which included patients with neuropathies secondary to collagen vascular disease, sarcoidosis, nutritional deficiency, and compression. Specifically, in 11 GBS patients in acute phase of illness, the titers of anti-PNM Ab were 6-to 56-fold greater than that found in normal controls without known disease. In 3 of 4 cases of chronic and recurrent polyneuritis and in all 5 paraproteinemia patients with neuropathy Ab titers were increased 9-to 50-fold over the controls.
The prevalence of anti-PNM Ab in GBS serum shown here contrasts sharply with previously reported incidences of 27% and 50o (3, 6) . Several clearance of anti-PNM Ab from the serum (Fig. 4) (Fig. 2) . The inability to show C1 fixation in 1 patient with chronic recurrent polyneuropathy could reflect absence of anti-PNM Ab but might also indicate the presence of IgG isotype recognizing an antigen with very low density (26) . IgG isotype appears to be responsible for Ab titers in 2 patients who had IgG monoclonal gammapathy. At present, we do not know whether the abnormal IgG in these patients is responsible for the Ab activities. Regardless, it should also be considered that all demyelination neuropathies may not have a common pathogenic mechanism in spite of clinical similarities. Patients with rheumatoid arthritis, systemic lupus erythematosis, and paraproteinemia without neuropathy were included as disease controls to evaluate the specificity of the assay for PNM antigens. Circulating immune complexes, various autoantibodies, and aggregated immunoglobulins did not appear to interfere with our assay. Low and probably insignificant titers (2 and 4) were found in 2 of 3 rheumatoid patients, all of whom had high titers of rheumatoid factor (Fig. 3) . Two patients with systemic lupus erythematosis and 2 with paraproteinemia did not show measurable C1 activation.
For Ab to be a factor in the initial phases of demyelination, it must penetrate a blood-nerve barrier, bind to presumably a surface antigen determinant on PNM or Schwann cells, and then mediate myelin destruction through activation of complement, Ab-dependent cytotoxic lymphocytes, or macProc. NatL Acad Sci. USA 821#11W) rophages. *Wid the C1FT assay, we have demonstrated the presence of complement-activating Ab reacting with surface PNM determinants in the serum of patients with actively demyelinating neuropathies. Demyelinating activity of GBS serum in vivo is reported highest early during the acute phase and falls with time (10, 12) in a manner similar to the Ab curve in 6 GBS patients followed serially in this study (Fig.  4) . The clearance of Ab in these patients correlated with a plateau in disease activity and clinical improvement. Although this may not prove Ab involvement in disease initiation, it clearly shows availability of a potentially myelin-destructive agent in the patient's serum. Other factors that stimulate Ab formation and allow access of Ab to PNM are unknown but obviously important in understanding the pathogenesis of immunologically mediated demyelination of peripheral nerve. Regardless, the significantly high titers of anti-PNM, Cl-fixing Ab demonstrated in all patients with acute-phase GBS, and in most patients with chronic and recurrent polyneuritis and paraproteinemia with peripheral neuropathy, suggest that the Ab may be a marker for primary peripheral demyelinating diseases.
